| Revenue growth | 19% YoY for FY26; 18% YoY for Q4 FY26. |
|---|---|
| Margins | Adjusted EBITDA margin improved from 12.7% to 13.4% in FY26. |
| Demand visibility | Strong growth in Chronic (53%) and Complex Generic (74%) portfolios. |
| Management confidence | High; citing 13 consecutive quarters of record revenue. |
Growth
Revenue grew 19% YoY to ₹904 Cr; Adjusted PAT increased 31% YoY to ₹83 Cr in FY26.
Outlook
Plant-6 OSD facility mechanical completion achieved; commercialization targeted for H1 FY27. Proposed dividend of ₹13 Cr.
Risks
Moderate industry volume growth (2.7% in IPM); lead times associated with export market regulatory approvals.
Earnings Call filed with NSE, NSE: WINDLAS. Summary written with AI assistance from the document.
Windlas Biotech Ltd: key numbers
- Share price
- ₹1,102.55
- Market cap
- ₹2,314 Cr
- Revenue (annual)
- ₹904.1 Cr
- Net profit (annual)
- ₹66.44 Cr
- P/E (TTM)
- 34.8×Sector 50.4×
- Promoter holding
- 63.31%+1.41% QoQ
- FII holding
- 2.04%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Windlas Biotech Ltd
All →Windlas Biotech Earnings Call Transcript: Key Takeaways
Windlas Biotech reported record quarterly revenue driven by 29% growth in CDMO vertical. Management focuses on operational excellence and capacity expansion via Plant 6 commercialization.
Windlas Biotech Investor Presentation: Key Takeaways
Windlas Biotech reported Q1FY27 revenue of ₹248 Cr (18% YoY). Adjusted EBITDA and PAT grew 26% and 37% respectively, excluding ESOP costs, driven by CDMO expansion.
Windlas Biotech Q1 FY27 Results: Net Profit ₹17.7 Cr, Up 0.0% YoY
Windlas Biotech Ltd reported revenue from operations of ₹248.1 Cr (+18.1% YoY) and net profit of ₹17.7 Cr (+0.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹17.7 Cr · +0.0% YoY
Windlas Biotech Earnings Call: Key Takeaways
Windlas Biotech reported record FY26 revenue of ₹904cr (up 19% YoY) and highest post-listing EPS of ₹31.60. Management emphasized scalability, capital efficiency (ROCE/ROE >25%), and diversification into injectables and exports.
Windlas Biotech Q4 FY26 Results: Net Profit ₹16 Cr, Down 1.8% YoY
Windlas Biotech Ltd reported revenue from operations of ₹238.5 Cr (+17.7% YoY) and net profit of ₹16 Cr (-1.8% YoY) for Q4 FY26.
- Key figure
- Net profit ₹16 Cr · -1.8% YoY